Retatrutide UK, Australia & International Availability
Retatrutide has produced the most dramatic weight loss numbers any obesity drug has ever achieved in a Phase 3 trial — 28.7% body weight reduction at 68 weeks. If you're in the UK, Australia, South Africa, or anywhere outside the US, you're almost certainly asking the same question: so when can I actually get it?
Key Takeaways
- Retatrutide is made by Eli Lilly and is still in Phase 3 clinical trials — unapproved in every country as of March 2026
- The UK's MHRA has not received a marketing authorisation application yet; realistic UK approval is late 2027 at the absolute earliest, more likely 2028
- Australia's TGA, South Africa's SAHPRA, and most other regulators are in the same waiting position as the MHRA
- Grey market peptide suppliers exist in the UK and internationally, but the legal and safety risks are real and specific
- If you want access today, international peptide suppliers who ship globally are the most practical option — with clear caveats
- NHS availability will come after MHRA approval and a NICE appraisal, adding another 6–18 months
The situation is genuinely frustrating if you've been tracking the trial data. Here's exactly where things stand across the major markets and what your actual options look like right now.
What Is Retatrutide and Why Is Everyone Talking About It
Retatrutide (development code LY3437943) is a synthetic peptide that activates three receptors simultaneously: GLP-1, GIP, and glucagon. That triple mechanism is the reason it outperforms every existing weight loss drug. Semaglutide (Wegovy) hits one receptor. Tirzepatide (Mounjaro) hits two. Retatrutide hits all three.
In December 2025, Eli Lilly published Phase 3 TRIUMPH-4 results. Participants with obesity and knee osteoarthritis lost an average of 28.7% of their body weight over 68 weeks — about 71 lbs (32.3 kg). Knee pain also dropped dramatically, with over 12% of patients reporting they were completely pain-free by the end of the study.
Seven more Phase 3 trials (TRIUMPH-1 through TRIUMPH-8) are expected to report throughout 2026. The full data package needed for regulatory submissions won't be complete until late 2026 at the earliest.
One side effect worth knowing about: dysesthesia — an abnormal tingling or burning sensation in the skin — occurred in 8.8% of patients on the 9 mg dose and 20.9% on the 12 mg dose. This is being closely watched in the remaining trials.
Retatrutide UK: Current Legal Status
Retatrutide is not approved for use in the UK. Full stop.
The MHRA (Medicines and Healthcare products Regulatory Agency) has not received a marketing authorisation application from Eli Lilly. That application can't happen until the full Phase 3 trial programme wraps up — which means late 2026 at the earliest for a filing. MHRA review typically takes around 150 working days (roughly 7–8 months) after a valid submission arrives.
Best-case timeline math: Phase 3 complete late 2026 → Eli Lilly files with MHRA early 2027 → MHRA approval late 2027. That's the optimistic scenario. Most analysts expect 2028.
After MHRA approval, the NHS still requires a separate NICE technology appraisal before it will fund prescriptions. NICE evaluations typically add 6–18 months. So NHS access realistically looks like 2029–2030.
Private prescriptions could theoretically come sooner after MHRA approval — potentially 2027–2028 if everything moves quickly. But that's still a couple of years away.
For more detail on when UK approval is expected, see our guide on when will retatrutide be available.
Retatrutide Where to Buy in the UK: Grey Market Reality
Search "retatrutide UK buy" and you'll find it. UK-based peptide suppliers and domestic grey market sites are selling vials labelled as retatrutide today.
The legal picture is complicated. Retatrutide without MHRA approval exists in a grey area. Peptides sold as "laboratory supplies" or for "non-human use" occupy a blurry regulatory space — technically not a licensed medicine, technically not fully banned either. What's clearly illegal is a seller making clinical health claims or a buyer trying to bring large quantities through customs.
The practical risks are more pressing than the legal ones:
- Purity is unverified. There's no GMP (Good Manufacturing Practice) requirement for grey market peptide sellers. The vial might contain the right compound, an incorrect concentration, or something else entirely.
- No dosing protocol. Retatrutide's optimal dosing is still being refined in trials. Phase 3 is testing 4 mg, 9 mg, and 12 mg with specific titration schedules. There's no established safe escalation guide for self-administration.
- No medical oversight. The dysesthesia issue found in TRIUMPH-4 at higher doses means someone needs to monitor your neurological response. You won't have that if you're self-injecting alone.
If you're determined to access retatrutide now rather than waiting for approval, an internationally-based supplier who ships to the UK is a more reliable sourcing option than domestic grey market sites, which tend to have inconsistent stock and no third-party testing.
Ascension Peptides ships internationally including to the UK →
For a full comparison of UK sourcing options, see where to buy retatrutide.
Retatrutide Australia: TGA Status
Australia's Therapeutic Goods Administration (TGA) has not approved retatrutide. It's not listed on the Australian Register of Therapeutic Goods (ARTG), meaning it cannot be legally prescribed or dispensed through standard Australian pharmacy channels.
The TGA evaluates drugs through its standard Prescription Medicines Authorisation pathway. Eli Lilly would need to file a submission, and like the MHRA, it won't do that until Phase 3 is complete.
However, Australia has one useful pathway: the TGA's Special Access Scheme (SAS), specifically SAS-B, which allows healthcare practitioners to prescribe unapproved therapeutic goods for individual patients in genuine clinical need. This requires:
- A registered medical practitioner to make the application
- Documented clinical justification
- Patient consent
SAS is not a back door for DIY purchases. It's a legitimate clinical pathway for patients who've exhausted approved options and have a doctor willing to apply. It's worth asking a GP or obesity specialist if you're in Australia and serious about this.
Outside the SAS pathway, Australian grey market peptide suppliers operate similarly to the UK — legally murky, quality unverified.
Retatrutide South Africa: SAHPRA Position
South Africa's regulatory body SAHPRA (South African Health Products Regulatory Authority) hasn't approved retatrutide either. South Africa typically follows EMA (European Medicines Agency) and FDA approvals with a delay of 1–3 years, and often requires a local submission.
For South African patients, the options today are:
- International sourcing — suppliers who ship globally can deliver to South Africa, though customs scrutiny varies
- Private clinics — some South African weight management clinics with international connections have explored compassionate use for selected patients
- Medical tourism — not relevant here since no country has approved it yet
If you're in South Africa and tracking this, the realistic approval timeline is 2029–2030 at best, assuming FDA and MHRA approvals land in 2027–2028 as expected.
Country-by-Country Status: Retatrutide International Availability
| Country | Regulatory Body | Current Status | Estimated Earliest Availability |
|---|---|---|---|
| United Kingdom | MHRA | No application filed — Phase 3 ongoing | Late 2027 (private Rx); 2029 (NHS) |
| Australia | TGA | Not listed on ARTG — SAS pathway possible | 2028–2029 |
| South Africa | SAHPRA | Unapproved — no application | 2029–2030 |
| United States | FDA | Phase 3 TRIUMPH ongoing — no filing yet | Late 2027 (earliest) |
| European Union | EMA | No filing — awaiting Phase 3 completion | 2028 |
| Canada | Health Canada | Phase 3 ongoing — no submission | 2028–2029 |
| New Zealand | Medsafe | Awaiting international approvals | 2029+ |
| India | CDSCO | No application — typically lags FDA by 2–4 years | 2030+ |
International Shipping: Getting Retatrutide Outside Your Home Country
No regulatory authority has approved retatrutide for human use, which means international shipment exists entirely in the unregulated peptide supply space.
A few practical realities if you're considering this route:
Customs risk varies by country. The UK, Australia, and Canada tend to scrutinise peptide imports more carefully than some other markets. Small personal quantities are generally less likely to be seized than bulk orders, but there's no guarantee.
Cold chain matters. Peptides degrade without proper cold storage. If a supplier is shipping internationally, you need to know how they handle refrigeration during transit. Many legitimate peptide suppliers use cold packs and insulated packaging; many don't.
Payment and verification. Reputable international peptide suppliers accept standard payment methods and publish third-party CoA (Certificate of Analysis) documents for their products. If a supplier only accepts crypto, bank transfer, or WhatsApp payments, walk away.
Reconstitution and dosing. Retatrutide typically arrives as a lyophilised (freeze-dried) powder that requires reconstitution with bacteriostatic water before injection. If you're not familiar with this process, it's a real safety consideration.
Ascension Peptides ships to the UK, Australia, South Africa, and most international destinations, with third-party tested products and transparent CoA documentation.
For pricing expectations across different markets, see our retatrutide cost guide.
How to Access Retatrutide Legally: Clinical Trials
The only completely above-board way to access retatrutide right now — in any country — is through a clinical trial.
Eli Lilly's TRIUMPH programme is running trials across multiple countries. To find active recruiting trials:
- Go to ClinicalTrials.gov and search "retatrutide"
- Use the location filter for your country (UK, Australia, South Africa, etc.)
- Check eligibility criteria — most TRIUMPH trials require a BMI of 30+ or 27+ with an obesity-related condition
- Register interest with the research centre directly
In the UK, you can also check Be Part of Research, which lists NHS and private trials recruiting across the country.
Clinical trial participation gives you access to the real compound, proper medical monitoring, and zero cost (Eli Lilly covers everything including travel in most trial protocols). The downside is eligibility screening and the possibility of being randomised to placebo.
How Retatrutide Compares to Available GLP-1 Options
While you're waiting, you're not without options. The approved GLP-1 medications available in the UK and Australia right now are genuinely effective:
| Medication | Mechanism | Avg. Weight Loss | Approval |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | ~15% over 68 weeks | UK, Australia ✓ |
| Tirzepatide (Mounjaro) | GLP-1 + GIP | ~20–22% over 72 weeks | UK ✓, Australia approved 2024 |
| Retatrutide | GLP-1 + GIP + Glucagon | ~28.7% over 68 weeks | Nowhere yet ✗ |
Tirzepatide in particular is available right now in the UK with a private prescription and is the closest thing to retatrutide's mechanism. If you're serious about weight loss and can't wait for retatrutide approval, it's the strongest option currently available.
What to Expect From Retatrutide: Dosage and Trial Protocols
Phase 3 TRIUMPH trials are testing three doses: 4 mg, 9 mg, and 12 mg, administered via subcutaneous injection once weekly. The titration schedule starts low (typically 2 mg for the first 4 weeks) and escalates gradually to reduce GI side effects.
Common side effects based on Phase 2 and TRIUMPH-4 data:
- Nausea (most common, especially during dose escalation)
- Diarrhoea and constipation
- Vomiting
- Dysesthesia — skin tingling/burning (8.8–20.9% at higher doses, unique to retatrutide)
- Decreased appetite
The dysesthesia finding is the most novel side effect profile compared to other GLP-1 drugs. It's not fully understood yet, but in TRIUMPH-4 it was generally manageable and didn't drive high rates of discontinuation.
Frequently Asked Questions
Q: Is retatrutide legal in the UK?
A: Retatrutide is not an approved medicine in the UK. It has no MHRA marketing authorisation. Selling or buying it as a medication is not lawful. Some sellers operate under "laboratory supply" labelling, which creates a grey area — but it doesn't make the product safe, tested, or medically supervised.
Q: When will retatrutide be available in the UK?
A: The realistic window for MHRA approval is late 2027 to 2028, assuming Eli Lilly files after completing Phase 3 trials in late 2026. NHS access requires an additional NICE appraisal, making 2029–2030 the most likely timeframe for NHS prescriptions. See our when will retatrutide be available.
Q: Can I get retatrutide in Australia?
A: Not through standard pharmacy channels. The TGA hasn't approved it. The SAS-B pathway allows a doctor to apply for unapproved medicines for individual patients — worth asking an obesity specialist about. International peptide suppliers also ship to Australia, though this carries the same quality and customs caveats as everywhere else.
Q: How does retatrutide compare to Mounjaro (tirzepatide)?
A: Retatrutide adds glucagon receptor activation on top of the GLP-1 + GIP targets that tirzepatide uses. In head-to-head trial data comparisons, retatrutide's 28.7% weight loss at 68 weeks significantly outperforms tirzepatide's 20–22%. However, tirzepatide is available now in the UK. Retatrutide is not.
Q: Where can I buy retatrutide that ships internationally?
A: Ascension Peptides ships internationally including to the UK, Australia, and South Africa. They provide third-party testing documentation. This is not a prescription service — see the disclaimer below.
Q: How much does retatrutide cost from grey market suppliers?
A: Pricing varies widely, but typical grey market vials (5 mg or 10 mg) run £60–£150 per vial in the UK, with monthly supply costs of £200–£500 depending on dosing. See our full retatrutide cost breakdown.
Q: Can I join a retatrutide clinical trial in the UK or Australia?
A: Yes, if you meet eligibility criteria. Check ClinicalTrials.gov for active TRIUMPH trial sites. UK residents can also use the NIHR's Be Part of Research portal. Most trials require a BMI of 30+ (or 27+ with comorbidities).
The Bottom Line
Retatrutide is almost certainly going to be approved — the Phase 3 data is too strong for it not to be. But approval takes time, and if you're in the UK, Australia, South Africa, or anywhere outside the US, you're looking at 2027 at the absolute earliest for any prescription access and 2028–2030 for realistic availability.
Your options today are: join a clinical trial (free, monitored, legitimate), use an international peptide supplier who ships to your country (legal grey area, quality varies), or start on an approved GLP-1 now while you wait.
If you're going the international sourcing route, use a supplier with verifiable third-party CoA documentation and a track record of shipping to your region.
Ascension Peptides — International shipping, third-party tested →
Medical Disclaimer: Retatrutide has not been approved by the MHRA, TGA, SAHPRA, FDA, or any other regulatory authority. This article is for informational purposes only. Nothing here constitutes medical advice. Do not self-administer any compound without consulting a qualified healthcare professional. Laws regarding peptide importation vary by country — check your local regulations before ordering.
